A decade of characterization

BioProcess International

Volumn 10, Issue SUPPL. 6, 2012, Pages 58-61

  Scott, Cheryl ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CONDUCTANCE; DRUG BIOAVAILABILITY; DRUG INDUSTRY; DRUG QUALITY; FOOD AND DRUG ADMINISTRATION; MASS SPECTROMETRY; PH; REVIEW;

EID: 84863542719     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (49)

1. Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach: Final Report. US Food and Drug Administration: Rockville, MD, September 2004.
2. Ritter NM. Distinctions Between Analytical and Bioanalytical Test Methods. BioProcess Int. 9(3) 2011: 80.
3. Schenerman MA, et al. CMC Strategy Forum Report: Analysis and Structure Characterization of Monoclonal Antibodies. BioProcess Int. 2(2) 2004: 42-52.
4. Simmerman H, Donnelly RP. Defining Your Product Profile and Maintaining Control Over It, Part 1: Session One of the WCBP CMC Strategy Forum, 19-20 July 2004. BioProcess Int. 3(6) 2005: 32-40.
5. Champion K, et al. Defining Your Product Profile and Maintaining Control Over It, Part 2: Challenges of Monitoring Host Cell Protein Impurities. BioProcess Int. 3(8) 2005: 52-57.
6. Boerner R, Clouse K. Defining Your Product Profile and Maintaining Control Over It, Part 3: Product-Related Impurities. BioProcess Int. 3(9) 2005: 50-56.
7. Brorson K, Phillips J. Defining Your Product Profile and Maintaining Control Over It, Part 4: Tackling Aggregates. BioProcess Int. 3(10) 2005: 50-54.
8. Apostol I, Kelner DN. Managing the Analytical Lifecycle for Biotechnology Products: A Journey from Method Development to Validation, Part One. BioProcess Int. 6(8) 2008: 12-19.
9. Apostol I, Kelner DN. Managing the Analytical Lifecycle for Biotechnology Products: A Journey from Method Development to Validation, Part Two. BioProcess Int. 6(9) 2008: 12-19.
10. Capen R, et al. Establishing Potency Specifications for Antigen Vaccines: Clinical Validation of Statistically Derived Release and Stability Specifications. BioProcess Int. 5(5) 2007: 30-42.
11. Scott C. Quality By Design and the New Process Validation Guidance. BioProcess Int. 9(5) 2011: 14-21.
12. Winter W. Analytical Instrument Qualification: Standardization on the 4Q Model. BioProcess Int. 4(9) 2006: 46-50.
13. Ritter N, et al. What Is Test Method Qualification? Proceedings of the WCBP CMC Strategy Forum, 24 July 2003. BioProcess Int. 2(8) 2004: 32-46.
14. Smith P. Trends in Analytical Instrument Qualification. BioProcess Int. 5(9) 2007: 30-38.
15. Brown DB, et al. Assay Validation for Rapid Detection of Mycoplasma Contamination. BioProcess Int. 7(4) 2009: 30-40.
16. Scott C. Analytical Methods for Biologics. BioProcess Int. 5(2) 2007: S35-S38.
17. Chait A, Zaslavsky B. Structural Signatures for Analysis and Characterization of Biological Products. BioProcess Int. 1(2) 2003: 60-67.
18. Defrancq L, et al. DSA-FACE: High-Throughput Analysis of the N-Glycans of NS0 Cell-Secreted Antibodies. BioProcess Int. 2(8) 2004: 60-68.
19. Jefferis R. Criteria for Selection of IgG Isotype and Glycoform Antibody Therapeutics. BioProcess Int. 4(9) 2006: 40-43.
20. Rosenfeld R, et al. High-Throughput Glycoanalysis for Biopharmaceutical Development and Manufacturing. BioProcess Int. 5(2) 2007: 38-47.
21. Bierau H, et al. Higher-Order Structure Comparison of Proteins Derived from Different Clones or Processes. BioProcess Int. 6(8) 2008: 52-59.
22. Que AH, et al. Sequence Variant Analysis Using Peptide Mapping By LC-MS/MS. BioProcess Int. 8(8) 2010: 52-60.
23. Wei Z, et al. The Role of Higher-Order Structure in Defining Biopharmaceutical Quality. BioProcess Int. 9(4) 2011: 58-66.
24. Michels DA, Salas-Solano O, Felten C. Imaged Capillary Isoelectric Focusing for Charge-Variant Analysis of Biopharmaceuticals. BioProcess Int. 9(10) 2011: 48-54.
25. Lundblad RL, Price NC. Protein Concentration Determination: The Achilles Heel of GMP? BioProcess Int. 2(1) 2004: 38-47.
26. Rau TD, Balcarcel RR. A 96-Well Plate Assay for Relative Monoclonal Antibody Titers. BioProcess Int. 4(3) 2006: 42-48.
27. Cronholm K, Johansson M. Determining Endotoxin Levels and Inhibition and Enhancement of the Endotoxin Reaction. BioProcess Int. 5(4) 2007: 78-83.
28. Wolter T, Richter A. Assays for Controlling Host-Cell Impurities in Biopharmaceuticals. BioProcess Int. 2(2) 2005: 40-46.
29. Venable D, et al. High-Throughput and Quantitative Detection of Residual NS0 and CHO Host-Cell Genomic DNA. BioProcess Int. 4(6) 2007: 56-61.
30. Mehta S, Keer JT. Performance Characteristics of Host-Cell DNA Quantification Methods. BioProcess Int. 4(9) 2007: 44-58.
31. Wang X, et al. Improved HCP Quantitation By Minimizing Antibody Cross-Reactivity to Target Proteins. BioProcess Int. 8(1) 2010: 18-24.
32. Schwertner D, Kirchner M. Are Generic HCP Assays Outdated? BioProcess Int. 8(5) 2010: 56-62.
33. Savino E, et al. Development of an In-House, Process-Specific ELISA for Detecting HCP in a Therapeutic Antibody, Part 1. BioProcess Int. 9(3) 2011: 38-47.
34. Savino E, et al. Development of an In-House, Process-Specific ELISA for Detecting HCP in a Therapeutic Antibody, Part 2. BioProcess Int. 9(4) 2011: 68-75.
35. Liu N, et al. Host Cellular Protein Quantification. BioProcess Int. 10(2) 2012: 44-50.
36. Gombold J, et al. Lot Release and Characterization Testing of Live-Virus-Based Vaccines and Gene Therapy Products, Part 1. BioProcess Int. 4(4) 2006: 46-54.
37. Gombold J, et al. Lot Release and Characterization Testing of Live-Virus-Based Vaccines and Gene Therapy Products, Part 2. BioProcess Int. 4(5) 2006: 56-65.
38. Towns J, Webber K. Demonstrating Comparability for Well-Characterized Biotechnology Products. BioProcess Int. 6(2) 2008: 32-43.
39. Scott C, McLeod LD. The Time Has Come for Automation in Bioprocessing. BioProcess Int. 8(2) 2010: 16-25.
40. Albert KJ. Automated Liquid Handlers As Sources of Error. BioProcess Int. 7(6) 2009: 56-60.
41. Krishnamurthy R, et al. Emerging Analytical Technologies for Biotherapeutics Development. BioProcess Int. 6(5) 2008: 32-42.
42. Robinson CJ, Little LE, Wallny HJ. Bioassay Survey 2006-2007. BioProcess Int. 6(3) 2008: 38-48.
43. Robinson CJ, et al. A Survey of Bioassays in the Biopharmaceutical Industry. BioProcess Int. 4(6) 2006: 24-36.
44. Rieder N, et al. The Roles of Bioactivity Assays in Lot Release and Stability Testing. BioProcess Int. 8(6) 2010: 33-42.
45. Das RG, Robinson CJ. Assessing Nonparallelism in Bioassays. BioProcess Int. 6(10) 2008: 36-56.
46. Menendez AT. Accelerating Bioassay Transfer in a GMP Environment. BioProcess Int. 7(11) 2009: 26-33.
47. Shivhare M, McCreath G. Practical Considerations for DoE Implementation in Quality By Design. BioProcess Int. 8(6) 2010: 22-30.
48. Vega-Mercado H, et al. HACCP: A Process Validation Tool for Ensuring Quality of Biotech and Pharmaceutical Products. BioProcess Int. 1(5) 2003: 50-57.
49. Montgomery SA. Operations and Quality Systems: Building in Success. BioProcess Int. 4(3) 2006: S58-S71.